By Cecilia Butini

Pharmaceutical giants Merck KGaA and GlaxoSmithKline PLC have decided to terminate their agreement on the development of cancer treatment bintrafusp alfa.

Merck said Thursday that the decision to terminate the agreement, which takes effect on Sept 30, was based on recent trial results which were less encouraging than earlier ones. The trial was named INTR@PID Lung 037, according to the U.S.-based company. Bintrafusp alfa is a bifunctional immunotherapy and its used was being investigated for difficult-to-treat cancers, including biliary tract cancer and cervical cancer, the company said.

Merck said GlaxoSmithKline didn't deliver any milestone payments and no future milestone obligations remain.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

September 30, 2021 10:42 ET (14:42 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Gsk.
Gsk (LSE:GSK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Gsk.